Wilms tumor, also known as nephroblastoma, is the most common malignant renal tumor of childhood, typically arising in children under the age of five. It develops from embryonal kidney tissue that fails to mature properly, and in a small but significant proportion of patients it appears in both kidneys simultaneously. Bilateral disease presents a particular therapeutic dilemma: surgeons must balance the need to remove cancerous tissue against the imperative to preserve enough functioning kidney for a lifetime of renal health. It is precisely this tension that has shaped the modern treatment paradigm, in which chemotherapy is given first to shrink the tumors, allowing later surgery to be as kidney-sparing as possible.

The central tenet of that paradigm is that diagnosis in typical cases can be made on clinical and radiological grounds alone. The Children’s Oncology Group in North America and the SIOP Renal Tumour Study Group in Europe and beyond are the two cooperative bodies whose protocols govern nearly all contemporary Wilms tumor treatment. Both groups discourage routine diagnostic biopsy in children whose imaging findings are characteristic, permitting it only in narrowly defined exceptions such as tumors that behave atypically on scans or cases where the diagnosis is genuinely uncertain. Crucially, neither group recommends biopsy of bilateral disease at initial presentation, because the imaging appearance of bilateral masses in a young child is considered sufficiently specific to justify starting neoadjuvant chemotherapy without histological confirmation.

The rationale behind this approach is not merely administrative. Upfront nephrectomy or biopsy can rupture or seed tumor cells, upstage disease, and complicate later surgical planning. More fundamentally, any invasive procedure performed before chemotherapy begins introduces a window of potential morbidity during which the child receives no anti-cancer therapy. In the case described by Aujla, that window proved disastrous. The biopsy of the right kidney, sampled at an outside facility prior to referral, returned a non-diagnostic result, providing no useful information while breaching the renal architecture. The left-sided sample did confirm Wilms tumor, but at a cost that would soon become apparent.

Within a short time, the child developed a draining sinus at the right biopsy site, discharging pus persistently. Clinical evaluation and subsequent surgical exploration revealed the underlying cause: a pelviureteric fistula, an abnormal communication between the renal collecting system and the ureter that allowed urine to leak into the tissues, creating a nidus for infection. Cultures identified Escherichia coli, and the infection proved refractory to standard management. For an 18-month-old already facing bilateral kidney tumors, the complication transformed a straightforward treatment pathway into a prolonged ordeal, with both the start of neoadjuvant chemotherapy and the timing of definitive surgery pushed back significantly.

The case is a textbook illustration of why the cooperative groups have drawn such firm lines around biopsy. A needle traversing the kidney does not simply sample tissue; it can lacerate the collecting system, provoke bleeding, and open a channel between a normally sterile urinary tract and the skin. In centers with immediate pediatric surgical, urological, and infectious disease support, such complications are rare and manageable. In resource-constrained settings, where imaging guidance may be limited and referral pathways circuitous, the same procedure can produce complications that are difficult to diagnose and harder to fix. The report emphasizes that this biopsy was performed outside a specialized pediatric oncology center, a detail that recurs in discussions of avoidable harm in childhood cancer care across low- and middle-income countries.

Yet the guidelines are not absolute, and the report takes care to situate the case within a nuanced evidence landscape. Emerging data have supported the safety of image-guided biopsy in specific unilateral cases, particularly where imaging is atypical and the differential diagnosis includes entities such as renal cell carcinoma that would change the surgical plan entirely. Aujla’s analysis, however, warns against extrapolating those findings to bilateral tumors. The hemodynamics, anatomy, and therapeutic strategy of bilateral disease are different: the goal is maximal nephron preservation after chemotherapy response has been assessed, and the protocols have built in a mechanism for exactly that. Under the Children’s Oncology Group’s AREN0534 protocol, for example, selective biopsy is permitted later in the treatment course, guided by the patient’s response to initial chemotherapy and performed before definitive surgery, when it can genuinely inform the extent of resection rather than merely confirm what imaging already suggested.

The historical arc of Wilms tumor management explains how this consensus emerged. Early surgical series treated the tumor as a straightforward resection problem, and upfront nephrectomy was standard. The National Wilms Tumor Study Group in the United States and its European counterpart, which later evolved into the SIOP framework, demonstrated in successive randomized trials that preoperative chemotherapy in Europe, and carefully sequenced surgery and chemotherapy in North America, produced survival rates that now exceed ninety percent for localized disease. Along the way, the trials also catalogued the harms of unnecessary intervention, including tumor rupture at surgery and the staging consequences of preoperative procedures. Biopsy, once considered a reasonable diagnostic step, was progressively restricted as imaging quality improved and the characteristic appearance of nephroblastoma became reliably recognizable on ultrasound and computed tomography.

For pediatricians, who are typically the first clinicians to encounter a child with an abdominal mass, the practical lesson is one of restraint and rapid referral. The report notes that premature referral for biopsy or upfront nephrectomy remains a recurring error, often driven by the instinct that tissue diagnosis must precede cancer treatment. In Wilms tumor, that instinct is inverted: in a young child with bilateral renal masses and typical imaging, the protocol-compliant move is to refer immediately to a pediatric oncology center and begin chemotherapy, reserving tissue sampling for the defined scenarios in which it changes management. Every week spent pursuing a non-diagnostic biopsy is a week of untreated disease and, as this case shows, a week in which iatrogenic injury can compound the burden of malignancy.

The broader significance of the report lies in its setting. Low- and middle-income countries face a disproportionate share of global childhood cancer deaths, and the reasons are structural: late presentation, fragmented referral systems, limited access to specialized pathology and imaging, and well-intentioned interventions at facilities without pediatric oncology capability. Case reports like this one function as evidence for systems-level change, arguing for clear referral pathways, education of frontline providers about protocol-based management, and restraint in procedures that guidelines explicitly discourage. The child at the center of this report ultimately faced both her tumor and its man-made complications, her treatment delayed by an infection that should never have had a route into her urinary tract. Her story, documented with the consent of her guardians and published openly, adds a human dimension to a statistical consensus, reminding clinicians everywhere that in pediatric oncology, following the protocol is not bureaucratic caution but a safeguard measured in kidneys, in infections avoided, and in time that no child with cancer can afford to lose.

Subject of Research: Complications of guideline-discordant renal biopsy in a child with suspected bilateral Wilms tumor

Article Title: Guideline-discordant biopsy in suspected bilateral Wilms tumor and its surgical complications: a case report from a low-resource setting and review of current protocols

Article References: Aujla, R. (2026). Guideline-discordant biopsy in suspected bilateral Wilms tumor and its surgical complications: a case report from a low-resource setting and review of current protocols. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07680-y

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07680-y

Keywords: Wilms tumor, bilateral renal disease, pediatric oncology, renal biopsy, SIOP-RTSG, Children's Oncology Group, AREN0534, neoadjuvant chemotherapy, pelviureteric fistula, needle biopsy complications, low-resource settings, BMC Pediatrics

Percutaneous renal biopsy, in which a thin needle is guided through the skin and into the kidney to extract a sliver of tissue, is a cornerstone of modern kidney medicine. It allows pathologists to diagnose glomerular diseases, assess inflammation, gauge the severity of transplant rejection, and guide treatment decisions that can alter the trajectory of a child’s kidney health for decades. The procedure is almost always performed under real-time ultrasound guidance, which lets the operator visualize the needle path and avoid large vessels. Yet even with this precision, bleeding remains the complication that defines the procedure’s risk profile. Blood vessels in the kidney operate under high pressure, and the organ’s rich blood supply means that even a small puncture can produce a hematoma, a pocket of clotted blood that forms around the biopsy site.

Most of what medicine knows about post-biopsy bleeding comes from studies in adults. Adult nephrology literature has identified a familiar cast of risk factors: advanced age, elevated serum creatinine, high blood pressure, anemia, larger biopsy needles, and the number of passes made with the needle. Pediatric patients, however, are not simply small adults. Their kidneys are smaller, their vascular anatomy differs, their blood volume is proportionally different, and the diseases that prompt biopsy in children, from minimal change disease to transplant rejection, follow their own patterns. When the researchers behind the new study surveyed the existing literature, they found that data on bleeding risk factors in children was strikingly limited, leaving pediatric teams to extrapolate from adult evidence that may not apply.

To close that gap, a team led by Rajkumar Meena and Gali Shapira-Zaltsberg at the Children’s Hospital of Eastern Ontario in Ottawa, working with biostatisticians Nick Barrowman and Anne Tsampalieros, conducted an institutional review board-approved retrospective study covering pediatric patients who underwent native or transplant kidney biopsies between 2010 and 2024. The study spanned fourteen years of clinical practice, capturing changes in technique, needle technology, and post-procedure care protocols over time. Because the study was retrospective and used de-identified data, the ethics board waived the requirement for individual informed consent, a standard approach for research that examines existing medical records rather than prospectively enrolling patients.

The researchers defined their outcomes with unusual precision. The primary endpoints were twofold: a drop in hemoglobin of more than 15 grams per liter measured four to six hours after the biopsy, and the presence of a sizable perinephric hematoma, defined as at least five milliliters of blood collected around the kidney, as seen on an ultrasound performed immediately after the procedure. The hemoglobin threshold matters because a fall of that magnitude in a child represents a meaningful loss of circulating blood volume, one that clinicians cannot afford to overlook. The five-milliliter hematoma threshold, meanwhile, distinguishes trivial traces of blood, which are common and usually harmless, from collections large enough to signal genuine vascular injury. The association between the presence of a hematoma and a significant hemoglobin drop was assessed directly, and the team analyzed twelve preselected risk factors for their connection to these co-primary outcomes.

The study population comprised 207 children, with a median age of 11 years and an interquartile range of 7 to 14, meaning half of the patients fell between those ages. Of these, 170 children, or 82 percent, underwent biopsy of their own kidneys, while 37 children, or 18 percent, had biopsies of transplanted kidneys. Transplant biopsies are a distinct procedural scenario: the graft sits in the iliac fossa of the pelvis rather than in the flank, its vascular supply differs, and the immune context of the patient is shaped by immunosuppressive therapy. Including both biopsy types gave the researchers a broad view of real-world pediatric practice, though it also meant the analysis had to accommodate two anatomically different procedures within a single cohort.

The headline result is a strong statistical association between what the immediate post-biopsy ultrasound shows and what happens to the child’s blood count. Twenty-three patients, or 11 percent of the cohort, experienced a hemoglobin decrease of at least 15 grams per liter, with a 95 percent confidence interval of 8 to 16 percent. Twenty-seven patients, or 13 percent, developed a perinephric hematoma of at least five milliliters, with a confidence interval of 9 to 18 percent. When the researchers cross-tabulated these outcomes, they found that children with a hematoma of five milliliters or more on immediate post-procedural imaging had roughly 4.6 times the odds of experiencing a significant hemoglobin decline compared with those who did not, with a 95 percent confidence interval of 1.5 to 13.4 and a p-value of 0.004. In practical terms, a child who leaves the biopsy suite with a measurable bleed around the kidney is several times more likely to be the child whose hemoglobin falls meaningfully in the hours that follow.

Just as telling is what the study did not find. The researchers examined twelve different preselected risk factors, a list that reflects the predictors repeatedly flagged in the adult literature, and after correcting for multiple statistical testing, none of the others showed a significant association with either hemoglobin decline or hematoma formation. This negative result carries real weight. It suggests that the conventional adult risk factors, and the demographic and procedural variables clinicians might instinctively reach for, do not reliably identify which children will bleed after a pediatric renal biopsy. The immediate ultrasound image, in other words, may be more informative than any characteristic of the patient measured before the needle goes in. The finding aligns with earlier work in adult populations, including Japanese and Chinese studies that examined ultrasonographic findings and renal parenchymal thickness as predictors of post-biopsy bleeding, but it extends that logic into pediatric practice, where the evidence base had been thin.

The implications for clinical practice are concrete. If a five-milliliter hematoma on immediate post-biopsy ultrasound predicts a meaningful hemoglobin drop, then that single image could serve as a triage tool. Children with a sizable hematoma might be flagged for closer observation, repeat hemoglobin checks, longer monitoring periods, or earlier involvement of the nephrology team, while children with a clean immediate scan might be candidates for streamlined discharge pathways. This matters in pediatric settings, where minimizing time in hospital and reducing unnecessary blood draws are priorities, and where the threshold for admitting a child for overnight observation varies widely between institutions. The study also underscores the value of standardized hematoma measurement; a recent scoping review of adult practice found that reporting of perirenal hematoma size after biopsy is inconsistent, making it difficult to compare studies or pool evidence. By defining a specific volumetric threshold, the Ottawa team offers a metric that other centers can adopt and validate.

There are, of course, limits to what a single-center retrospective study can establish. The cohort of 207 patients, while respectable for a pediatric procedure study, yields relatively few bleeding events, and the wide confidence intervals around the estimates reflect that statistical uncertainty. The twelve risk factors examined were preselected, and other variables not captured in the records, such as subtle differences in technique or patient hydration status, could conceivably play a role. The hematoma-hemoglobin association, while statistically robust, is an association observed in retrospective data rather than a demonstrated causal pathway, and the finding awaits validation in independent, ideally multi-center, pediatric cohorts before it should drive wholesale changes to monitoring protocols. Still, the study’s message is clear and clinically actionable: in children undergoing ultrasound-guided kidney biopsy, the most valuable predictor of clinically significant bleeding may not be found in the chart at all, but on the ultrasound screen in the minutes immediately after the biopsy needle is withdrawn. For a procedure performed thousands of times each year in children’s hospitals around the world, that is a finding worth watching.

Subject of Research: Risk factors for clinically significant hemorrhage after ultrasound-guided percutaneous renal biopsy in children

Article Title: Predictors of clinically significant hemorrhage following ultrasound-guided percutaneous renal biopsy in pediatric patients

Article References: Meena, R., Barrowman, N., Tsampalieros, A., & Shapira-Zaltsberg, G. (2026). Predictors of clinically significant hemorrhage following ultrasound-guided percutaneous renal biopsy in pediatric patients. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06794-w

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06794-w

Keywords: renal biopsy, pediatric nephrology, hemorrhage, ultrasound, perinephric hematoma, hemoglobin decline, kidney transplant biopsy, interventional radiology, post-biopsy monitoring, risk factors, Pediatric Radiology, retrospective study